JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB31891

Anti-ErbB2 / HER2 Affibody® Molecule (FITC)

Be the first to review this product! Submit a review

|

(11 Publications)

Anti-ErbB2 / HER2 Affibody® Molecule (FITC) suitable for Flow Cyt, ICC/IF, IHC-Fr. Cited in 10 publications.

View Alternative Names

CD340, HER2, MLN19, NEU, NGL, ERBB2, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, MLN 19

1 Images
Immunocytochemistry/ Immunofluorescence - Anti-ErbB2 / HER2 Affibody® Molecule (FITC) (AB31891)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-ErbB2 / HER2 Affibody® Molecule (FITC) (AB31891)

Human mammary gland cell line SK-BR3 cells were stained with fluorescin conjugated Anti-ErbB2 / HER2 Affibody® molecule (ab31891). The staining was localized to the membrane of the ErbB 2 expressing human mammary gland cells. Nuclei were counter stained with DAPI (blue fluorescence). The SK-BR3 cells were stained for 30 minutes at a concentration of 1-5ug Affibody® molecule/ml.

Key facts

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IHCFr" : {"fullname" : "Immunohistochemistry (Frozen sections)", "shortname":"IHC-Fr"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "predicted", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCFr-species-checked": "predicted", "IHCFr-species-dilution-info": "", "IHCFr-species-notes": "" }, "": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IHCFr-species-checked": "testedAndGuaranteed", "IHCFr-species-dilution-info": "", "IHCFr-species-notes": "<p>Staining of paraffin embedded tissues is not recommended.</p><p>AFFIBODY<sup>®</sup> MOLECULES ARE PROTOCOL SPECIFIC. PLEASE REFER TO THE \"PROTOCOLS\" LINKS BELOW.</p>" } } }

Product details

This product is a recombinant protein produced in E.coli.

What are Affibody Molecules?
Affibody® affinity ligands are unique research reagents, produced using innovative protein-engineering technologies. They are small, simple proteins composed of a three-helix bundle based on the scaffold of one of the IgG-binding domains of Protein A. Protein A is a surface protein from the bacterium Staphylococcus aureus. This scaffold has excellent features as an affinity ligand and can be designed to bind with high affinity to any given target protein. The domain consists of 58 amino acids, 13 of which are randomized to generate Affibody® libraries with a large number of ligand variants. Thus, the libraries consist of a multitude of protein ligands with an identical backbone and variable surface-binding properties. In function, Affibody® Molecules mimic monoclonal antibodies. Compared to antibodies, the most striking dissimilarity of Affibody® Molecules is the small size. Affibody® Molecules have a molecular weight of 6kDa, compared to the molecular weight of antibodies, which is 150kDa. In spite of its small size, the binding site of Affibody® Molecules is similar to that of an antibody. The advantages of Affibody® Molcules over antibodies are: -their small size -the simple structure of the molecules -its robust physical properties; able to withstand a broad range of analytical conditions, including extreme pH and elevated temperature -its ability to fold correctly intracellularly -the fast and cost effective production in bacteria -the potential to couple Affibody® Molecules in multimeric constructs Affibody® Molecules have highly competitive properties for applications within affinity purification, sample preparation, protein detection and in vitro diagnostics.

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The ErbB2 also known as HER2 or HER2 protein is a transmembrane receptor protein with a molecular weight of about 185 kDa. It serves as part of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. The ErbB2 protein is expressed mainly in epithelial tissues including those of the breast and the gastrointestinal tract. It lacks a known ligand-binding domain which sets it apart from other members of its family. Due to its structure ErbB2 dimerizes with other members of the EGFR family to exert its effects in cellular signaling.
Biological function summary

The role of ErbB2 extends beyond a singular function. It becomes an active component when forming heterodimers with other EGFR family members such as ErbB3 to initiate various downstream signaling cascades. The dimerization activates intracellular pathways leading to cell proliferation survival differentiation and migration. Within cells ErbB2 influences processes critical for normal development and tissue homeostasis contributing significantly to signal transduction networks.

Pathways

ErbB2 plays a pivotal role in pathways such as the PI3K/Akt and MAPK/ERK pathways. These pathways are important in mediating cellular responses to growth signals. The PI3K/Akt pathway activated by HER2 signaling regulates cell growth and survival while the MAPK/ERK pathway contributes to cell differentiation and proliferation. ErbB2's interaction with proteins like ErbB3 is fundamental in these pathways increasing the amplitude and diversity of downstream signals.

ErbB2 is significantly associated with breast cancer and gastric cancer. The overexpression or gene amplification of HER2 is observed in approximately 20% of breast cancer cases correlating with aggressive tumor growth and poor prognosis. ErbB2-related signaling contributes to oncogenic processes by promoting excessive cell proliferation. Targeting ErbB2 in these cancers is common using therapies such as monoclonal antibodies like trastuzumab. In the context of gastric cancer the role of ErbB2 mirrors its function in breast cancer and targeting HER2 holds therapeutic potential.

Product protocols

Target data

Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.. In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth.
See full target information ERBB2

Publications (11)

Recent publications for all applications. Explore the full list and refine your search

Science advances 10:eadk9944 PubMed39630893

2024

A trafficking regulatory subnetwork governs αβ integrin-HER2 cross-talk to control breast cancer invasion and drug resistance.

Applications

Unspecified application

Species

Unspecified reactive species

Horacio Maldonado,Marcel Dreger,Lara D Bedgood,Theano Kyriakou,Katarzyna I Wolanska,Megan E Rigby,Valeria E Marotta,Justine M Webster,Jun Wang,Emma V Rusilowicz-Jones,John F Marshall,Judy M Coulson,Iain R Macpherson,Adam Hurlstone,Mark R Morgan

Cancers 12: PubMed33213060

2020

Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Oncolytic Virus.

Applications

Unspecified application

Species

Unspecified reactive species

Guendalina Froechlich,Carmen Caiazza,Chiara Gentile,Anna Morena D'Alise,Maria De Lucia,Francesca Langone,Guido Leoni,Gabriella Cotugno,Vittorio Scisciola,Alfredo Nicosia,Elisa Scarselli,Massimo Mallardo,Emanuele Sasso,Nicola Zambrano

Frontiers in oncology 10:191 PubMed32185126

2020

miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines.

Applications

Unspecified application

Species

Unspecified reactive species

Lihi Ninio-Many,Elad Hikri,Tamar Burg-Golani,Salomon M Stemmer,Ruth Shalgi,Irit Ben-Aharon

Oncotarget 9:27736-27751 PubMed29963233

2018

ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Karineh Petrossian,Noriko Kanaya,Chiao Lo,Pei-Yin Hsu,Duc Nguyen,Lixin Yang,Lu Yang,Charles Warden,Xiwei Wu,Raju Pillai,Lauren Bernal,Chiun-Sheng Huang,Laura Kruper,Yuan Yuan,George Somlo,Joanne Mortimer,Shiuan Chen

Human pathology 77:35-44 PubMed29555575

2018

ACOT1 expression is associated with poor prognosis in gastric adenocarcinoma.

Applications

IHC-P

Species

Human

Fang Wang,Jingyi Wu,Zhichao Qiu,Xiaosong Ge,Xingxiang Liu,Chun Zhang,Wenhuan Xu,Fengming Wang,Dong Hua,Xiaowei Qi,Yong Mao

Journal of immunology research 2017:3908289 PubMed29104875

2017

A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies.

Applications

Flow Cyt

Species

Human

Christophe Lallemand,Feifei Liang,Flore Staub,Maud Simansour,Benoit Vallette,Lue Huang,Rosa Ferrando-Miguel,Michael G Tovey

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20:416-427 PubMed27517839

2016

PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Yasunori Deguchi,Hiroshi Okabe,Nobu Oshima,Shigeo Hisamori,Sachiko Minamiguchi,Manabu Muto,Yoshiharu Sakai

Molecular therapy : the journal of the American Society of Gene Therapy 22:1029-38 PubMed24572294

2014

Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.

Applications

Unspecified application

Species

Unspecified reactive species

Anat Globerson-Levin,Tova Waks,Zelig Eshhar

OncoTargets and therapy 6:693-701 PubMed23814468

2013

Human epidermal growth factor receptor 2-positive breast cancer: which cytotoxic agent best complements trastuzumab's efficacy in vitro?

Applications

Flow Cyt

Species

Human

Tracey Hurrell,Kim Outhoff

Molecular oncology 7:440-51 PubMed23290417

2013

Targeting HER2-positive cancer cells with receptor-redirected anthrax protective antigen.

Applications

Unspecified application

Species

Unspecified reactive species

Andrew J McCluskey,Andrew J Olive,Michael N Starnbach,R John Collier
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com